CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre-B-cell acute lymphoblastic leukaemia

Br J Haematol. 2021 Apr;193(1):171-175. doi: 10.1111/bjh.17161. Epub 2021 Feb 23.

Abstract

Disease relapse is the greatest cause of treatment failure in paediatric B-cell acute lymphoblastic leukaemia (B-ALL). Current risk stratifications fail to capture all patients at risk of relapse. Herein, we used a machine-learning approach to identify B-ALL blast-secreted factors that are associated with poor survival outcomes. Using this approach, we identified a two-gene expression signature (CKLF and IL1B) that allowed identification of high-risk patients at diagnosis. This two-gene expression signature enhances the predictive value of current at diagnosis or end-of-induction risk stratification suggesting the model can be applied continuously to help guide implementation of risk-adapted therapies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Chemokines / genetics*
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Infant
  • Interleukin-1beta / genetics*
  • MARVEL Domain-Containing Proteins / genetics*
  • Machine Learning / statistics & numerical data*
  • Male
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Predictive Value of Tests
  • Recurrence
  • Risk Assessment / standards
  • Survival Analysis
  • Transcriptome / genetics
  • Treatment Failure

Substances

  • CKLF protein, human
  • Chemokines
  • IL1B protein, human
  • Interleukin-1beta
  • MARVEL Domain-Containing Proteins